SCALE OF
THE PROBLEM
An estimated 300 million people worldwide face moderate to high cardiovascular risk, a number that’s only set to increase as our population ages.
UNMET
MEDICAL NEEDS
Advancements in healthcare have gifted us with a global life expectancy of 73 years.
Now, we strive to extend not just life, but quality of life, aiming to exceed the current health span average of 64 years.
Helixism INVESTOR
Ken / Bo-En Lin
I have worked for German medical device company BIOTRONIK and American medical device company MEDTRONIC for a total of 10 years. Before transitioning to ABIES Asset Management, I held the position of Deputy Director for the Business Unit at BIOTRONIK. During this period, I also got to know many doctors. With long-term exposure, I have accumulated considerable knowledge and insight into the clinical applications and practical therapies of medical devices, which is beneficial for business expansion. ABIES Asset Management is committed to investing in biomedical startups that aim to improve human health and optimize the quality of life. Currently, we have investments in biomedical companies based in the United States, Taiwan, and Singapore.
About invest in Helixism Biomedical
01
What motivated you to primarily invest in Helixism Biomedical?
Taiwan has now entered an aging society, where especially older people are more dependent on medical care. We anticipate that Taiwan’s market demand for the health industry will grow even more rapidly in the future, and there is a need for good medical devices in the market. Helixism Biomedical has strong R&D capabilities, particularly focusing on the development of non-invasive External Counter Pulsation (ECP) devices, which aligns with market demand. In addition to this, Helixism Biomedical has already obtained invention patents in both the United States and Taiwan, with multiple patent applications in progress. These are all the reasons I considered for investing.
02
What‘s your opinion on Helixism Biomedical’s management team?
Helixism Biomedical’s management team consists of two co-founders. One is Professor Yang Fu-Liang, who is currently working at the Scientific Research Center for Applied Sciences, Academia Sinica. He has spent years specializing in the R&D of non-invasive treatments and diagnostic medical devices. The other co-founder is General Manager Zhong Chang-Gui, who has extensive experience in high-level processes and R&D within the semiconductor electronics industry. After three years of collaborative R&D between Professor Yang and General Manager Zhong, they successfully developed the Helical External Counter Pulsation system (HECP) and received the National Innovation Award. Helixism Biomedical was founded in 2021, and KF, the Chief Strategy Officer, also joined the company in 2022, primarily responsible for market development and investor relations management. Together, the trio has established a strong foundation in R&D, manufacturing, and operational capabilities.
03
How did KF, chief strategy officer of Helixism Biomedical, and you meet?
We two met at the Shi Fu Angel Club. On one hand, there’s a company focused on the research of non-invasive cardiovascular disease treatments; on the other, a company committed to investing in improving human health. Their business philosophies aligned well, setting the stage for a collaborative relationship.
04
From an investment standpoint, what future prospects do you envision for Helixism Biomedical Inc?
By 2030, Taiwan’s senior population is projected to surpass 5.5 million, indicating a shift towards home-based care, community clinics, and extended-day care centers for the elderly. In anticipation of this trend, Helixism Biomedical has successfully developed the intelligent and compact Helical External Counter Pulsation (HECP) system. We are eager to see Helixism Biomedical’s solutions reach a broader demographic, both in Taiwan and globally, who could benefit from External Counter Pulsation therapy. At ABIES Asset Management, we believe investment should go beyond market demand and potential to focus on industries that positively impact human health and well-being. This makes our investment not just valuable, but also deeply meaningful. In partnership with Helixism, we aim to contribute to a healthier, better society.
